Denmark
· Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 43.10 billion. The enterprise value is 34.44 billion.
| Market Cap | 43.10B |
| Enterprise Value | 34.44B |
Important Dates
The last earnings date was Thursday, February 20, 2025.
| Earnings Date | Feb 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 70.65 million shares outstanding. The number of shares has increased by 17.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 70.65M |
| Shares Change (YoY) | +17.40% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 0.28% |
| Owned by Institutions (%) | 53.34% |
| Float | 60.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.00 |
| P/TBV Ratio | 5.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -31.93 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -36.61 |
Financial Position
The company has a current ratio of 21.14, with a Debt / Equity ratio of 0.05.
| Current Ratio | 21.14 |
| Quick Ratio | 21.11 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.42 |
| Interest Coverage | -37.27 |
Financial Efficiency
Return on equity (ROE) is -21.13% and return on invested capital (ROIC) is -14.80%.
| Return on Equity (ROE) | -21.13% |
| Return on Assets (ROA) | -13.81% |
| Return on Invested Capital (ROIC) | -14.80% |
| Return on Capital Employed (ROCE) | -13.94% |
| Revenue Per Employee | 187,137 |
| Profits Per Employee | -3.22M |
| Employee Count | 335 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.85 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.77% in the last 52 weeks. The beta is 0.54, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +2.77% |
| 50-Day Moving Average | 728.35 |
| 200-Day Moving Average | 788.86 |
| Relative Strength Index (RSI) | 36.54 |
| Average Volume (20 Days) | 192,546 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 62.69 million and -1.08 billion in losses. Loss per share was -16.24.
| Revenue | 62.69M |
| Gross Profit | 54.82M |
| Operating Income | -1.27B |
| Pretax Income | -1.08B |
| Net Income | -1.08B |
| EBITDA | -1.26B |
| EBIT | -1.27B |
| Loss Per Share | -16.24 |
Balance Sheet
The company has 8.23 billion in cash and 391.76 million in debt, giving a net cash position of 8.65 billion or 122.49 per share.
| Cash & Cash Equivalents | 8.23B |
| Total Debt | 391.76M |
| Net Cash | 8.65B |
| Net Cash Per Share | 122.49 |
| Equity (Book Value) | 8.62B |
| Book Value Per Share | 121.96 |
| Working Capital | 8.12B |
Cash Flow
In the last 12 months, operating cash flow was -930.82 million and capital expenditures -10.05 million, giving a free cash flow of -940.87 million.
| Operating Cash Flow | -930.82M |
| Capital Expenditures | -10.05M |
| Free Cash Flow | -940.87M |
| FCF Per Share | -13.32 |
Margins
| Gross Margin | 87.44% |
| Operating Margin | -2,024.33% |
| Pretax Margin | -1,728.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.40% |
| Shareholder Yield | -17.40% |
| Earnings Yield | -2.50% |
| FCF Yield | -2.18% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 32.27.
| Altman Z-Score | 32.27 |
| Piotroski F-Score | n/a |